Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 8/20 | 0.64 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2801497 | 0.98 | EPHX1 (0.67) | EPHX1GAAMAPK1HTTSMN1; SMN2 | |
| SCHEMBL26677284 | 0.96 | EPHX1 (0.59) | EPHX1GAAMAPK1HTTSMN1; SMN2 | |
| SCHEMBL14424446 | 0.95 | EPHX1 (0.67) | EPHX1GAAMAPK1HTTSMN1; SMN2 | |
| SCHEMBL21059112 | 0.93 | EPHX1 (0.69) | EPHX1GAAMAPK1HTTSMN1; SMN2 | |
| SCHEMBL4719490 | 0.93 | GAA (0.59) | EPHX1GAAMAPK1HTTSMN1; SMN2 | |
| SCHEMBL13387564 | 0.93 | GAA (0.59) | EPHX1GAAMAPK1HTTSMN1; SMN2 | |
| SCHEMBL1690687 | 0.92 | EPHX1 (0.68) | EPHX1GAAMAPK1HTTSMN1; SMN2 | |
| SCHEMBL10811922 | 0.92 | EPHX1 (0.68) | EPHX1GAAMAPK1HTTSMN1; SMN2 | |
| SCHEMBL28059725 | 0.92 | EPHX1 (0.68) | EPHX1GAAMAPK1HTTSMN1; SMN2 | |
| SCHEMBL16146100 | 0.90 | GAA (0.54) | EPHX1GAAMAPK1HTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110183974-A1 | 1,2,4-OXADIAZOLE SUBSTITUTED PIPERIDINE AND PIPERAZINE DERIVATIVES AS SMO ANTAGONISTS | INSTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI (IT) | 2011-07-28 | — | — | US | disclosed |
| EP-2318400-A1 | 1,2,4-OXADIAZOLE SUBSTITUTED PIPERIDINE AND PIPERAZINE DERIVATIVES AS SMO ANTAGONISTS | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. (IT) | 2011-05-11 | — | — | EP | disclosed |
| WO-2010013037-A1 | 1,2,4-OXADIAZOLE SUBSTITUTED PIPERIDINE AND PIPERAZINE DERIVATIVES AS SMO ANTAGONISTS | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A. (IT) | 2010-02-04 | — | — | WO | disclosed |
| EP-1829876-A1 | NITROGENEOUS TRICYCLIC COMPOUND | Asahi Kasei Pharma Corporation (JP) | 2007-09-05 | — | — | EP | disclosed |
| CN-1257889-C | Novel amino acid derivatives, process for their preparation and pharmaceutical compositions containing them | SERVIER LAB (FR) | 2006-05-31 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110183974-A1 | 1,2,4-OXADIAZOLE SUBSTITUTED PIPERIDINE AND PIPERAZINE DERIVATIVES AS SMO ANTAGONISTS | SHH, SMO, GLI1 | EPHX1 2252/4885GAA 4330/4885MAPK1 749/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.